Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery | springermedicine.com

Springer Medicine

Top

Journal of Neuro-Oncology

Published in:

01-12-2009 | Laboratory Investigation - Human/animal tissue

Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery

Authors: Seunguk Oh, John R. Ohlfest, Deborah A. Todhunter, Vincent D. Vallera, Walter A. Hall, Hua Chen, Daniel A. Vallera

Published in: Journal of Neuro-Oncology | Issue 3/2009

Login to get access

Abstract

A bispecific ligand-directed toxin (BLT) consisting of human interleukin-13, epithelial growth factor, and the first 389 amino acids of diphtheria toxin was assembled in order to target human glioblastoma. In vitro, DTEGF13 selectively killed the human glioblastoma cell line U87-luc as well as other human glioblastomas. DTEGF13 fulfilled the requirement of a successful BLT by having greater activity than either of its monospecific counterparts or their mixture proving it necessary to have both ligands on the same single chain molecule. Aggressive brain tumors established intracranially (IC) in nude rats with U87 glioma genetically marked with a firefly luciferase reporter gene were treated with two injections of DTEGF13 using convection enhanced delivery resulting in tumor eradication in 50% of the rats which survived with tumor free status at least 110 days post tumor inoculation. An irrelevant BLT control did not protect establishing specificity. The bispecific DTEGF13 MTD dose was measured at 2 µg/injection or 0.5 μg/kg and toxicity studies indicated safety in this dose. Combination of monospecific DTEGF and DTIL13 did not inhibit tumor growth. ELISA assay indicated that anti-DT antibodies were not generated in normal immunocompetent rats given identical intracranial DTEGF13 therapy. Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study.

1.

Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6:1909–1919. doi:10.1158/1535-7163.MCT-07-0047 CrossRefPubMed

2.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

3.

Todhunter DA, Hall WA, Vallera DA et al (2004) A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157–164. doi:10.1093/protein/gzh023 CrossRefPubMed

4.

Vallera DA, Chen H, Sicheneder AR et al (2009) Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. doi:10.1016/j.leukres.2009.02.006

5.

Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA (2007) Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 13:3058–3067. doi:10.1158/1078-0432.CCR-06-2454 CrossRefPubMed

6.

Stish BJ, Oh S, Vallera DA et al (2008) Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol 87:51–61. doi:10.1007/s11060-007-9499-8 CrossRefPubMed

7.

Schmidt M, Hynes NE, Groner B, Wels W (1995) A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 65:538–546. doi:10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4 CrossRef

8.

Dukecohan JS, Morimoto C, Schlossman SF (1993) Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation 56:1188–1196CrossRef

9.

Shen G, Li J, Vitetta ES (1994) A bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells, but not T cells in vitro and shows both A chain-mediated and LAK-T mediated killing. J Immunol 152:2368–2376PubMed

10.

Stish BJ, Chen H, Panoskaltsis-Mortari A, Vallera DA (2007) A bispecific recombinant cytotoxin (DTEGF13) targeting human IL-13 and EGF receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 13:6486–6493. doi:10.1158/1078-0432.CCR-07-0938 CrossRefPubMed

11.

Vallera DA, Shu Y, Stish BJ et al (2008) Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 57:634–641. doi:10.1136/gut.2007.137802 CrossRefPubMedPubMedCentral

12.

Debinski W, Obiri NI, Puri RK et al (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1:1253–1258PubMed

13.

Debinski W, Gibo DM, Gillespie GY et al (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5:985–990PubMed

14.

Debinski W, Slagle B, Gillespie GY et al (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48:103–111. doi:10.1023/A:1006446426611 CrossRefPubMed

15.

Husain SR, Joshi BH, Puri RK et al (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92:168–175. doi:10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N CrossRefPubMed

16.

Husain SR, Puri RK (2003) Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65:37–48. doi:10.1023/A:1026242432647 CrossRefPubMed

17.

Engebraaten O, Hjortland GO, Fodstad O et al (2002) Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97:846–852. doi:10.1002/ijc.10137 CrossRefPubMed

18.

Liu TF, Hall PD, Frankel AE et al (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329–334PubMed

19.

Liu TF, Willingham MC, Frankel AE et al (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107–1114. doi:10.1021/bc034111+ CrossRefPubMed

20.

Liu TF, Tatter SB, Frankel AE et al (2003) Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2:783–787PubMed

21.

Yamaizumi M, Mekada E, Okada Y et al (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245–250. doi:10.1016/0092-8674(78)90099-5 CrossRefPubMed

22.

Williams DP, Snider CE, Murphy JR et al (1990) Structure/function analysis of interleukin-2-toxin (DAB486-IL-2) Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 265:11885–11889PubMed

23.

Collier RJ (1975) Diphtheria toxin: mode of action and structure. Bacteriol Rev 39:54–85PubMedPubMedCentral

24.

Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat Med 3:1362–1368. doi:10.1038/nm1297-1362 CrossRefPubMed

25.

Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, Low WC, Freese AB, Largaespada DA (2005) Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 5:778–788. doi:10.1016/j.ymthe.2005.07.689 CrossRef

26.

Vallera DA, Todhunter D, Chen H et al (2005) Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res 29:331–341. doi:10.1016/j.leukres.2004.08.006 CrossRefPubMed

27.

Benaron DA, Contag PR, Contag CH (1997) Imaging brain and function, infection and gene expression in the body using light. Philos Trans R Soc Lond B Biol Sci 352:755–761. doi:10.1098/rstb.1997.0059 CrossRefPubMedPubMedCentral

28.

Rustamzadeh E, Hall WA, Vallera DA et al (2007) Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 120:411–419. doi:10.1002/ijc.22278 CrossRefPubMed

29.

Rustamzadeh E, Hall WA, Vallera DA et al (2006) Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 118:2594–2601. doi:10.1002/ijc.21647 CrossRefPubMed

30.

Vallera DA, Ash RC, Youle RJ et al (1983) Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222:512–515. doi:10.1126/science.6353579 CrossRefPubMed

31.

Kreitman RJ, Squires DR, Pastan I et al (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729. doi:10.1200/JCO.2005.11.437 Sep 20CrossRefPubMed

32.

Souweidane MM, Occhiogrosso G, Edgar MA et al (2004) Interstitial infusion of IL-13-PE38QQR in the rat brain stem. J Neurooncol 67:287–293. doi:10.1023/B:NEON.0000024219.47447.91 CrossRefPubMed

33.

Myklebust AT, Godal A, Fodstad O (1994) Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res 54:2146–2150PubMed

34.

Hjortland GO, Garman-Vik SS, Engebraaten O et al (2004) Immunotoxin treatment targeted to the high-molecular weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100:320–327CrossRefPubMed

35.

McKenzie AN, Zurawski G (1995) Interleukin-13: characterization and biologic properties. Cancer Treat Res 80:367–378CrossRefPubMed

36.

Elleman TC, Domagala T, Nerrie M et al (2001) Identification of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 40:8930–8939. doi:10.1021/bi010037b CrossRefPubMed

37.

Parsa AT, Chakrabarti I, Bruce JN et al (2000) Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery 47:993–999. doi:10.1097/00006123-200010000-00050 CrossRefPubMed

38.

Vitetta ES (2000) Immuntoxin and vascular leak syndrome. Cancer J 6:S218–S224PubMed

39.

Baluna R, Vitetta ES (1999) An in vivo model to study of immuntoxin-induced vascular leak syndrome in human tissue. J Immunother 22:41–47. doi:10.1097/00002371-199901000-00006 CrossRefPubMed

40.

Kioi M, Husain SR, Puri RK et al (2006) Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 5:239–250CrossRefPubMed

41.

Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105:11311–11316. doi:10.1073/pnas.0804851105 CrossRefPubMedPubMedCentral

42.

Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA (2009) Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin DTEGF13 and convection enhanced delivery. J Neurooncol (in press)

43.

Juweid M, Neumann R, Weinstein JN et al (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier. Cancer Res 52:5144–5153PubMed

44.

Saga T, Neumann RD, Weinstein JN et al (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92:8999–9003. doi:10.1073/pnas.92.19.8999 CrossRefPubMedPubMedCentral

45.

Kroll RA, Pagel MA, Neuwelt EA et al (1996) Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 38:746–752. doi:10.1097/00006123-199604000-00024 CrossRefPubMed

46.

Sampson JH, Akabani G, Archer GE et al (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumor. Neurooncology 10:320–329. doi:10.1215/15228517-2008-012

47.

Kunwar S, Prados MD, Chang SM et al (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844. doi:10.1200/JCO.2006.08.1117 CrossRefPubMed

48.

Oh S, Odland R, Wilson SR et al (2007) Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 107:568–577. doi:10.3171/JNS-07/09/0568 CrossRefPubMed

49.

Sung C, Dedrick RL, Youle RJ et al (1993) The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography. Cancer Res 53:2092–2099PubMed

50.

Jain RK (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9:253–266. doi:10.1007/BF00046364 CrossRefPubMed

51.

Fujimori K, Covell DG, Weinstein JN et al (1990) A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31:1191–1198PubMed

52.

Zurawski G, de Vries JE (1994) Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 12:169–174CrossRefPubMed

Title: Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery
Authors: Seunguk Oh
John R. Ohlfest
Deborah A. Todhunter
Vincent D. Vallera
Walter A. Hall
Hua Chen
Daniel A. Vallera
Publication date: 01-12-2009
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-9932-2

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties